胃肠间质瘤分子靶向治疗耐药机制及对策  

Resistance and treatment strategy of gastrointestinal stromal tumor target therapy

作　　者：陆巍[1] 陆维祺[1] 

机构地区：[1]复旦大学附属中山医院普通外科,上海200032

出　　处：《中华胃肠外科杂志》2012年第3期309-312,共4页Chinese Journal of Gastrointestinal Surgery

摘　　要：胃肠间质瘤（GIST）是一种特殊类型的间叶源性肿瘤．伊马替尼和舒尼替尼等小分子靶向药物是除手术外治疗GIST有效治疗方法。然而部分肿瘤对伊马替尼和（或）舒尼替尼存在原发性或继发性耐药。基因突变类型的差异以及继发基因突变是导致耐药的主要原因。临床上一旦出现肿瘤耐药．应根据耐药种类、耐药原因以及肿瘤具体情况．制订合理而个体化的治疗策略，提高治疗效果，改善生存质量。Gastrointestinal stromal tumor （GIST） originates from interstitial cells of Cajal （tCCs）. Tyrosine kinase inhibitors （TKI） such as imatinib and sunitinib, are effective agents besides surgery. However some GIST can become primarily or secondarily resistant to those drugs. The difference in gene mutation types and secondary gene mutation is the main cause. When the GIST is proved to be drug resistance, reasonable personal treatment strategies based on individualized medicine should be made to improve outcomes and quality of life.

关 键 词：胃肠间质瘤 靶向治疗 耐药 治疗策略 

分 类 号：R735[医药卫生—肿瘤]